Bullish case
$140 to $160
More likely if pro forma organic growth holds above 4%, adjusted margins recover, China portfolio cleanup reduces complexity, and the market keeps valuing RVTY near a premium life science tools multiple.
Revvity, Inc. research snapshot
RVTY AI Stock Analysis
RVTY AI stock analysis currently reads Revvity, Inc. as a focused life sciences and diagnostics platform with solid cash generation, improving organic growth, and a cleaner portfolio after its PerkinElmer transformation. At the July 8, 2026 cutoff, RVTY traded near $112.05 with a market capitalization near $12.5 billion. The analysis is constructive on business durability but cautious on valuation because GAAP earnings, leverage, China portfolio actions, and end-market recovery still matter. This page is informational only and not investment advice.
Current price
$112.05
Market cap
$12.5 billion
AI score
67 / 100
Rating
Quality health science platform with valuation and margin risk
Trend status
Short-term uptrend, near resistance after a sharp rebound
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. Revvity has long public filings, current quarterly releases, investor materials, third-party financial databases, and active analyst coverage.
- bias Check
- The main AI bias risk is over-weighting the clean health science transformation story while under-weighting margin compression, leverage, China immunodiagnostics divestiture timing, and the fact that public consensus is already well informed.
- ai Confidence
- High data confidence
- investment Certainty
- Medium. Data quality is strong, but investment certainty is lower because the upside case depends on sustained organic growth, adjusted margin recovery, and a valuation multiple that already discounts better conditions.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Revvity sells reagents, instruments, software, services, reproductive health tests, and immunodiagnostics used in drug discovery, genomics, imaging, and diagnostic workflows. | High |
| Moat | The moat comes from workflow integration, regulated diagnostic relationships, specialized content, software, consumables, and customer validation costs, but scale is smaller than Danaher or Thermo Fisher. | Medium-high |
| Management | CEO Prahlad Singh has led the portfolio repositioning, share repurchases, and the planned China Immunodiagnostics divestiture; execution is visible but still being tested through the next cycle. | Medium-high |
| Financial trend | Fiscal 2025 revenue rose 3.7% to $2.856 billion, Q1 2026 revenue rose 7%, and free cash flow stayed healthy, while adjusted margins compressed year over year. | High |
| Valuation | At about 54x trailing GAAP EPS, 20x forward EPS, and 25x to 26x free cash flow, the stock needs growth and margin recovery to justify a large re-rating. | Medium-high |
| Technical trend | RVTY has a positive intermediate setup after rising 13% over two weeks, but it trades close to short-term resistance near $112.84 to $114.56. | Medium |
| Risk level | Risk is medium. Main risks are life science funding cycles, diagnostic demand, China divestiture execution, debt, tariff and mix pressure, and valuation sensitivity. | Medium-high |
| AI confidence | High confidence for reported financial facts and current technical levels, lower confidence for margin timing and end-market recovery speed. | High data confidence |
| Investment certainty | Medium certainty because business quality is real, but the current price leaves less room for weak organic growth or another margin setback. | Medium |
RVTY AI stock forecast
RVTY AI Stock Forecast Scenarios
The RVTY AI stock forecast uses scenario ranges rather than a point prediction. The valuation tool indicates a wide three-year range because small changes in adjusted EPS growth and exit multiple have a large effect on value.
Base case
$110 to $120
More likely if adjusted EPS grows in the low to mid single digits, the forward multiple stays near 20x, and cash flow supports buybacks without a major balance sheet strain.
Bearish case
$75 to $85
More likely if life science customer budgets weaken, diagnostics growth slows, tariffs or mix keep margins under pressure, or investors value RVTY closer to a slower-growth diagnostics peer.
RVTY AI technical analysis
RVTY AI Technical Analysis
RVTY AI technical analysis uses the July 7, 2026 close of $112.05 because this static page does not fetch request-time chart data. The stock was in a strong short-term rising trend, but near-term reward looked less attractive while price sat close to resistance.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $112.05 | Closing price reported for July 7, 2026 and used as the technical data cutoff. |
| Near resistance | $112.84 to $114.56 | Accumulated-volume and Fibonacci resistance were clustered close to the latest close. |
| Breakout reference | $114.48 to $116.05 | A move through this zone would suggest the short-term trend is extending rather than stalling. |
| Volume support | $101.22 and $99.09 | These were the nearest accumulated-volume support levels below the current price. |
| Short-term moving average | $112.44 | Price was slightly below the short-term average, creating a near-term resistance signal. |
| Long-term moving average | $102.46 | Price remained above the long-term average, which kept the broader trend signal constructive. |
| Momentum | Positive but extended | The stock was up 13.14% over the prior two weeks, so chasing after the move carries higher timing risk. |
| Volume | Rising on a down day | Higher volume with a lower close can warn that short-term sellers are active near resistance. |
| Volatility | Medium, 3.26% one-week average daily move | Position sizing should allow for normal daily swings near earnings and guidance updates. |
| Invalidation | Sustained close below $101 | A break below the first support cluster would weaken the current rebound setup. |
RVTY AI trading strategy
RVTY AI Trading Strategy Framework
The RVTY AI trading strategy is a rules-based framework, not a personalized instruction. It should be paired with position sizing, earnings-date awareness, and a written invalidation level.
Trend-following setup
Wait for RVTY to reclaim short-term resistance near $112.84 to $114.56 with confirmation from volume and a stable market tape.
Reduce confidence if the breakout fails quickly or if price closes back below the short-term moving average after earnings-related news.
Mean-reversion setup
If RVTY pulls back toward $101 to $103 without a change in fundamentals, review whether the long-term moving average and volume support are still holding.
Do not average down below support unless the Q2 2026 earnings setup, guidance, and China divestiture details have been updated.
Fundamental monitor
Track pro forma organic growth, adjusted operating margin, free cash flow, debt reduction, share count, and segment mix in Life Sciences and Diagnostics.
Reset valuation if adjusted EPS guidance moves below the $5.20 to $5.30 range or if free cash flow weakens while leverage remains high.
Investment research summary
Four-master Research Compression
Business essence
Revvity helps researchers, biopharma companies, labs, and healthcare systems run specialized discovery and diagnostic workflows through instruments, reagents, software, testing content, and services.
Moat
The moat is based on workflow know-how, regulated customer validation, installed instruments, repeat consumables, diagnostics relationships, and software, but the company competes against larger and well-funded platforms.
Munger risk inversion
The thesis can fail if customers delay life science spending, China immunodiagnostics divestiture value disappoints, debt limits flexibility, or adjusted earnings prove less cash-backed than recent results suggest.
Management
Management has reshaped the former PerkinElmer portfolio toward Life Sciences and Diagnostics, using buybacks and divestitures while trying to restore organic growth and margin quality.
Industry trend
Drug discovery, genomics, reproductive health, newborn screening, and diagnostic automation remain long-duration health science trends, but funding and purchasing cycles can be uneven.
Valuation and margin of safety
The current price implies confidence in low to mid single digit organic growth and adjusted margin recovery. Margin of safety is limited if GAAP EPS stays low or the forward multiple compresses.
Source-backed data
RVTY Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| RVTY price | $112.05 at the July 7, 2026 close | StockInvest.us RVTY technical snapshot | July 8, 2026 |
| Market capitalization | $12.5 billion, verified with financial_rigor.py using $112.05 and 111.56 million shares at 0.00% variance | StockInvest.us quote and StockAnalysis statistics | July 8, 2026 |
| Shares outstanding | 111.56 million to 111.80 million recent share range | StockAnalysis statistics and CompaniesMarketCap shares outstanding | July 8, 2026 |
| Fiscal 2025 revenue | $2.856 billion, up 3.7% from fiscal 2024 | Revvity FY2025 earnings release | July 8, 2026 |
| Q1 2026 revenue | $711 million reported revenue, 7% growth, 3% organic growth, and 6% pro forma organic growth | Revvity Q1 2026 earnings release | July 8, 2026 |
| FY2026 pro forma guidance | $2.81 billion to $2.84 billion revenue, 3% to 4% pro forma organic growth, and $5.20 to $5.30 pro forma adjusted EPS | Revvity Q1 2026 earnings release | July 8, 2026 |
| Cash and debt | $860.32 million cash and equivalents, $3.35 billion total debt, and $2.49 billion net debt | StockAnalysis balance sheet | July 8, 2026 |
| Free cash flow | $509.41 million in fiscal 2025 and $492.69 million TTM | StockAnalysis income statement | July 8, 2026 |
| Valuation | 53.6x trailing GAAP EPS, 20.4x forward EPS, 4.3x sales, and 25.4x free cash flow | StockAnalysis statistics | July 8, 2026 |
| Technical levels | Resistance near $112.84 to $114.56, support near $101.22 and $99.09, and 52-week range of $81.22 to $118.30 | StockInvest.us RVTY technical snapshot | July 8, 2026 |
Frequently Asked Questions
Read the REGN AI stock analysisExplore MDT AI technical analysisView the AI Stock PickerGenerate an AI trading strategy
This RVTY AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast scenarios are based on available public data as of July 8, 2026 and can be wrong if earnings, guidance, interest rates, industry demand, or market conditions change.